Skip to content

Illumina Wins FTC Antitrust Case Over Grail Acquisition

  • FTC alleged deal would harm innovation in cancer detection
  • European regulators still reviewing deal, which closed in 2021
Updated on

Illumina Inc. won a US Federal Trade Commission lawsuit seeking to unwind its $7 billion acquisition of cancer-startup Grail Inc. after an administrative judge ruled the tie-up didn’t violate antitrust law, the company said.

The FTC said it’s reviewing the decision and evaluating next steps. The agency last year sued in its in-house court to block the merger, which it alleged would harm innovation for early-stage cancer detection tests.